Janney Montgomery Scott LLC decreased its holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB – Free Report) by 11.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 90,285 shares of the biotechnology company’s stock after selling 11,996 shares during the period. Janney Montgomery Scott LLC owned 0.07% of Seres Therapeutics worth $432,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. E Fund Management Co. Ltd. lifted its stake in shares of Seres Therapeutics by 18.5% in the 4th quarter. E Fund Management Co. Ltd. now owns 16,667 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 2,597 shares during the last quarter. Credit Suisse AG lifted its stake in shares of Seres Therapeutics by 4.1% in the 2nd quarter. Credit Suisse AG now owns 90,359 shares of the biotechnology company’s stock valued at $309,000 after purchasing an additional 3,532 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Seres Therapeutics by 0.8% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 572,991 shares of the biotechnology company’s stock valued at $3,680,000 after purchasing an additional 4,282 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Seres Therapeutics by 5.2% in the 1st quarter. Rhumbline Advisers now owns 94,302 shares of the biotechnology company’s stock valued at $535,000 after purchasing an additional 4,689 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Seres Therapeutics by 2.2% in the first quarter. Bank of New York Mellon Corp now owns 225,526 shares of the biotechnology company’s stock worth $1,605,000 after buying an additional 4,907 shares during the period. Institutional investors own 87.93% of the company’s stock.
Seres Therapeutics Price Performance
Shares of Seres Therapeutics stock opened at $1.53 on Wednesday. The company has a debt-to-equity ratio of 4.45, a current ratio of 3.23 and a quick ratio of 3.16. The business has a 50 day simple moving average of $2.43 and a two-hundred day simple moving average of $4.08. The stock has a market capitalization of $196.16 million, a P/E ratio of -1.23 and a beta of 2.71. Seres Therapeutics, Inc. has a 12 month low of $1.27 and a 12 month high of $9.49.
Analyst Ratings Changes
Separately, StockNews.com started coverage on Seres Therapeutics in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.67.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
- Five stocks we like better than Seres Therapeutics
- The How And Why of Investing in Oil Stocks
- Caterpillar crawls into a new buying opportunity
- What is the Euro STOXX 50 Index?
- Is there merit in these low-beta moat stocks? Analysts say yes
- What is the Dogs of the Dow Strategy? Overview and Examples
- Oil swings have led analysts to recommend these 2 stocks
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.